Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Current Deferred Revenue: 2024-2025

Historic Current Deferred Revenue for Prime Medicine (PRME) over the last 1 years, with Sep 2025 value amounting to $7.0 million.

  • Prime Medicine's Current Deferred Revenue fell 25.10% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 25.10%. This contributed to the annual value of $7.1 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Prime Medicine reported Current Deferred Revenue of $7.0 million as of Q3 2025, which was down 16.40% from $8.3 million recorded in Q2 2025.
  • Over the past 5 years, Prime Medicine's Current Deferred Revenue peaked at $9.3 million during Q3 2024, and registered a low of $7.0 million during Q3 2025.
  • Its 2-year average for Current Deferred Revenue is $8.0 million, with a median of $8.2 million in 2025.
  • Data for Prime Medicine's Current Deferred Revenue shows a maximum YoY decreased of 25.10% (in 2025) over the last 5 years.
  • Over the past 2 years, Prime Medicine's Current Deferred Revenue (Quarterly) stood at $7.1 million in 2024, then declined by 25.10% to $7.0 million in 2025.
  • Its Current Deferred Revenue stands at $7.0 million for Q3 2025, versus $8.3 million for Q2 2025 and $8.2 million for Q1 2025.